MiR-4492, a New Potential MicroRNA for Cancer Diagnosis and Treatment: A Mini Review.

Chonnam medical journal Pub Date : 2024-01-01 Epub Date: 2024-01-25 DOI:10.4068/cmj.2024.60.1.21
Aida Alizamir, Mohammad Amin Amini, Ashkan Karbasi, Mehdi Beyrami
{"title":"MiR-4492, a New Potential MicroRNA for Cancer Diagnosis and Treatment: A Mini Review.","authors":"Aida Alizamir, Mohammad Amin Amini, Ashkan Karbasi, Mehdi Beyrami","doi":"10.4068/cmj.2024.60.1.21","DOIUrl":null,"url":null,"abstract":"<p><p>There is no doubt that the incidence of cancer sufferers is rising in the world, and it is estimated that in the next several decades, the number of people suffering from malignancies or the cancer rate will double. Diagnostic and therapeutic targeting of noncoding RNAs (ncRNAs), especially microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), represent an excellent approach for cancer diagnosis and treatment, as well as many other diseases. One of the latest miRNAs is miR-4492, upregulating some genes in tumor tissues including ROMO1, HLA-G, NKIRAS2, FOXK1, and UBE2C. It represents an attractant example of a miRNA acting at multiple levels to affect the same malignancy hallmark. Based on the studies, miR-4492 plays a key role in several cancers such as, breast cancer, bladder cancer, osteosarcoma, glioblastoma multiforme, hepatocellular carcinoma, colorectal cancer, and ovarian cancer. Putting it all together, identifying the precise mechanisms of miR-4492 in the pathogenesis of cancer, could pave the way to find better diagnostic and therapeutic strategies for cancer sufferers. For this reason, it might be a novel potential diagnostic biomarker and therapeutic target for neoplasms.</p>","PeriodicalId":94372,"journal":{"name":"Chonnam medical journal","volume":"60 1","pages":"21-26"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10828084/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chonnam medical journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4068/cmj.2024.60.1.21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/25 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

There is no doubt that the incidence of cancer sufferers is rising in the world, and it is estimated that in the next several decades, the number of people suffering from malignancies or the cancer rate will double. Diagnostic and therapeutic targeting of noncoding RNAs (ncRNAs), especially microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), represent an excellent approach for cancer diagnosis and treatment, as well as many other diseases. One of the latest miRNAs is miR-4492, upregulating some genes in tumor tissues including ROMO1, HLA-G, NKIRAS2, FOXK1, and UBE2C. It represents an attractant example of a miRNA acting at multiple levels to affect the same malignancy hallmark. Based on the studies, miR-4492 plays a key role in several cancers such as, breast cancer, bladder cancer, osteosarcoma, glioblastoma multiforme, hepatocellular carcinoma, colorectal cancer, and ovarian cancer. Putting it all together, identifying the precise mechanisms of miR-4492 in the pathogenesis of cancer, could pave the way to find better diagnostic and therapeutic strategies for cancer sufferers. For this reason, it might be a novel potential diagnostic biomarker and therapeutic target for neoplasms.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
MiR-4492,一种用于癌症诊断和治疗的新型潜在 MicroRNA:微型综述。
毫无疑问,全球癌症发病率正在上升,据估计,在未来几十年内,恶性肿瘤患者人数或癌症发病率将翻一番。以非编码 RNA(ncRNA),特别是微小 RNA(miRNA)和长非编码 RNA(lncRNA)为诊断和治疗靶标,是诊断和治疗癌症以及许多其他疾病的绝佳方法。最新的 miRNA 之一是 miR-4492,它能上调肿瘤组织中的一些基因,包括 ROMO1、HLA-G、NKIRAS2、FOXK1 和 UBE2C。它是 miRNA 在多个水平上影响同一恶性肿瘤特征的一个引人入胜的例子。根据研究,miR-4492 在乳腺癌、膀胱癌、骨肉瘤、多形性胶质母细胞瘤、肝细胞癌、结直肠癌和卵巢癌等多种癌症中发挥着关键作用。综上所述,确定 miR-4492 在癌症发病机制中的确切机制,可以为癌症患者找到更好的诊断和治疗策略铺平道路。因此,miR-4492 可能是一种新型的潜在肿瘤诊断生物标志物和治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Anomalous Origin of the Right Coronary Artery from the Pulmonary Artery. Beaver Tail Liver: A Morphological Study of Variation in the Left Lobe of the Liver. Comparison of Synergistic Sedation with Midazolam and Propofol Versus Midazolam and Pethidine in Colonoscopies: A Prospective, Randomized Controlled Study. Corticosteroid Therapy Duration and Dosage According to the Timing of Treatment Initiation for Post-COVID-19 Organizing Pneumonia. Design, Implementation and Evaluation of a Health Promotion Program for Family Caregivers of Chronic Mental Disorders: A Mixed Methods Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1